Stockreport

Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference [Yahoo! Finance]

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com
PDF for tezepelumab, has a natural ~23-day half-life suggesting possible dosing every 2–3 months, and is in a Phase II atopic dermatitis trial with topline data expected in [Read more]